Page last updated: 2024-10-26

dipyridamole and Kidney Neoplasms

dipyridamole has been researched along with Kidney Neoplasms in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Kidney Neoplasms: Tumors or cancers of the KIDNEY.

Research Excerpts

ExcerptRelevanceReference
"One potential explanation for why renal cell carcinoma is usually poorly responsive to chemotherapy is intrinsic multidrug resistance."2.67A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. ( Grosh, W; Loehrer, PJ; Murphy, BR; Pennington, KL; Rynard, SM, 1994)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Murphy, BR1
Rynard, SM1
Pennington, KL1
Grosh, W1
Loehrer, PJ1

Trials

1 trial available for dipyridamole and Kidney Neoplasms

ArticleYear
A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

1994